These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33523317)

  • 1. Intravenous immunoglobulin as the rescue treatment in NMOSD patients.
    Lin J; Xue B; Zhu R; Pan J; Li J; Lin Y; Li X; Xia J
    Neurol Sci; 2021 Sep; 42(9):3857-3863. PubMed ID: 33523317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add-on therapy in acute attacks of neuromyelitis optica spectrum disorder.
    Siwach G; Hans R; Takkar A; Ahuja CK; Lamba DS; Lal V; Sharma RR
    J Clin Apher; 2024 Jun; 39(3):e22129. PubMed ID: 38850074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder.
    Lin J; Xue B; Chen Z; Huang X; Pang W; Quan W; Huang Y; Li X; Xia J
    Int J Neurosci; 2017 Jun; 127(6):508-515. PubMed ID: 27323840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
    Pizzolato Umeton R; Waltz M; Aaen GS; Benson L; Gorman M; Goyal M; Graves JS; Harris Y; Krupp L; Lotze TE; Shukla NM; Mar S; Ness J; Rensel M; Schreiner T; Tillema JM; Roalstad S; Rodriguez M; Rose J; Waubant E; Weinstock-Guttman B; Casper C; Chitnis T;
    Neurology; 2023 Feb; 100(9):e985-e994. PubMed ID: 36460473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD).
    Li X; Tian DC; Fan M; Xiu Y; Wang X; Li T; Jia D; Xu W; Song T; Shi FD; Zhang X
    Mult Scler Relat Disord; 2020 Sep; 44():102325. PubMed ID: 32653803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder.
    Mealy MA; Levy M
    Medicine (Baltimore); 2019 Jun; 98(25):e15944. PubMed ID: 31232925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
    Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
    Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.
    Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX
    Front Immunol; 2023; 14():1257955. PubMed ID: 37915570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
    Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
    Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
    Yaguchi H; Sakushima K; Takahashi I; Nishimura H; Yashima-Yamada M; Nakamura M; Tsuzaka K; Maruo Y; Takahashi T; Yabe I; Sasaki H
    Intern Med; 2013; 52(9):969-72. PubMed ID: 23648715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.